Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BC3402 + azacitidine
- Development stage
- Phase 1
- Lead developer
- Biocity Biopharmaceutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BC3402 + azacitidine is a combination investigational therapy being evaluated for safety, pharmacokinetics, pharmacodynamics, and efficacy in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)[1][3]. BC3402 is a novel agent (precise mechanism not disclosed in public trial records) and azacitidine is a DNA demethylating small molecule used to treat bone marrow disorders; azacitidine inhibits DNA methyltransferase and incorporates into RNA and DNA to exert anti-neoplastic and cytotoxic effects[2][6]. The combination is administered intravenously in clinical trials targeting patients ineligible for stem cell transplantation[1][3].
- Other names
- BC3402 + azacitidine
02
Targets
HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on BC3402 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BC3402 + azacitidine.